Sign in
TerminatedPhase 2/3

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Key facts

Who runs it
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2/3
People taking part
62 people enrolled
Started
22 Jun 2021
Ended
17 Apr 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SHR-1701、 BP102 、XELOX
  • placebo、 BP102、 XELOX
Record updated
18 May 2025
Why it stopped
Adjustment of the Company's R\&D Strategy

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients with unresectable recurrent or metastatic adenocarcinoma of the colon or rectum confirmed histologically
  • For subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
  • At least 1 measurable lesion according to RECIST V1.1
  • The vital organs are functioning well
  • ECOG score is 0 ~ 1
  • Contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug

Who cannot take part

  • Recurrent or metastatic lesions can be treated with radical surgery
  • Poorly controlled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the case of regular antihypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy
  • Subject with current interstitial pneumonia or interstitial lung disease, or with a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy
  • Previous treatment with targeted T cell costimulatory molecules and immune checkpoint inhibitors;Previous treatment with antiepidermal growth factor receptor or any antiangiogenic drug
  • Severe cardiovascular and cerebrovascular diseases;Have clinical heart symptoms or diseases that are not well controlledSubjects with a history of myocardial infarction or unstable angina pectoris
  • Presence of central nervous system or meningeal metastases
  • Moderate and severe ascites of clinical symptoms;Uncontrolled or moderate or greater pleural effusion or pericardial effusion

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.

The 3 groups in the trial

  • SHR-1701 in combination with BP102 and XELOX(Phase 2)Treatment being tested

    Treatment: SHR-1701、 BP102 、XELOX

  • SHR-1701 in combination with BP102 and XELOX (Phase 3)Treatment being tested

    Treatment: SHR-1701、 BP102 、XELOX

  • placebo in combination with BP102 and XELOXPlacebo, for comparison

    Treatment: placebo、 BP102、 XELOX

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Study of SHR-1701 or Placebo in Combination With BP102 (Biosimilar to Bevacizumab) and XELOX in First-line Treatment of mCRC
Publications
Record updated
18 May 2025